Filing Flows › Immunocore Holdings (IMCR) › Stock forecast & fair value
Immunocore Holdings (IMCR) stock forecast and fair value
Immunocore Holdings (IMCR) trades at $29.39. 9 analysts' median price target is $55.00 (+87%), from $33.00 to $100.00. Across 17 valuation methods the middle fair value is $35.49 (+21%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $66.42 | $72.83 | $142.29 | +148% |
| EV/Sales vs peers, weighted | $47.04 | $61.48 | $72.06 | +109% |
| EV/Sales vs peers, matched | $18.01 | $18.64 | $26.52 | -37% |
| EV/Sales vs peers, growth & margin adjusted | $63.15 | $88.17 | $124.84 | +200% |
| Residual income | $4.53 | $4.71 | $4.89 | -84% |
| Analysts' price targets | $33.00 | $58.33 | $100.00 | +98% |
| Path-to-margin DCF | $26.36 | $35.79 | $45.22 | +22% |
| Path-to-margin DCF, dilution-adjusted | $26.36 | $35.79 | $45.22 | +22% |
| Exit-multiple (venture) method | $12.89 | $23.91 | $54.95 | -19% |
| EV/Sales vs Rule of 40 (all-company fit) | $15.69 | $26.70 | $56.92 | -9% |
Immunocore Holdings' latest quarter
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IMCR stock?
The median of 9 analysts' 12-month targets is $55.00, +87% from $29.39; the range is $33.00 to $100.00. The average rating is buy.
What is Immunocore Holdings' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $4.71 and $88.17, with a middle value of $35.49 against a price of $29.39. Each method's assumptions are on the page.
Does Immunocore Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is IMCR stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.